Chloroquinedrug info
chloroquine phosphate 250 MG Oral Tablet
What it is used for
Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ).
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective July 8, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
Chloroquine phosphate tablet, USP, is a 4-aminoquinoline compound for oral administration. It is a white, crystalline powder, freely soluble in water, practically insoluble in alcohol (ethanol 96%), in chloroform and in ether. Chloroquine phosphate tablet is an antimalarial and amebicidal drug. Chemically, it is 7-chloro-4-[[4- (diethylamino)-1-methylbutyl]amino] quinoline phosphate (1:2) and has the following structural formula: Each tablet contains 250 mg and 500 mg of chloroquine phosphate USP, equivalent to 150 mg and 300 mg chloroquine base respectively.
Inactive Ingredients: Anhydrous citric acid, hydrogenated vegetable oil, lactose monohydrate, magnesium stearate, corn starch, pregelatinized starch and starch. For chloroquine phosphate USP, 250 mg FDA approved dissolution test specifications differ from USP. 1
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective July 8, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance